MDL Track
MDL 2846
S.D. Ohio
Bard/Davol polypropylene hernia mesh
23,695 pending
Medical Device · claims involving Bard and Davol polypropylene mesh failures, adhesion, migration, and revision surgery
Defendant
C.R. Bard, Inc.
MDL / Track
MDL 2846
S.D. Ohio
Judge
Judge Edmund A. Sargus, Jr.
Plaintiffs
~23,698 pending (23,695 per JPML March 2, 2026 report, plus ~3 new filings tracked since)
Bellwether / Trial
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
C.R. Bard agreed in October 2024 to pay over $1 billion to settle approximately 38,000 claims in MDL 2846 (In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation), centralized before Judge Edmund A. Sargus, Jr. in the Southern District of Ohio. The global settlement framework, with a Qualified Settlement Fund established December 16, 2024, employs a points-based allocation system tied to injury severity, revision-surgery history, and product identification. The settlement followed a split bellwether record—one defense verdict (Johns, July 2021), one plaintiff verdict on defective design ($255,000, Milanesi, April 2022), and one plaintiff verdict on failure-to-warn ($500,000, Stinson, November 2023)—plus a $4.8 million state-court plaintiff verdict in Rhode Island (Trevino, 2022).
Causation Theory
Plaintiffs allege Bard's polypropylene mesh products—including Ventralex ST, Ventralight ST, 3DMax, Perfix Plug, Sepramesh IP Composite, and Composix—are defectively designed for permanent implantation because polypropylene degrades in vivo, triggering foreign-body response, mesh migration, contraction, fragmentation, and adhesion to bowel, bladder, or surrounding tissue. Internal Bard documents produced in discovery showed the company possessed engineering analyses, medical literature reviews, and adverse event tracking documenting these polypropylene risks years before litigation, yet failed to adequately warn physicians. The failure-to-warn theory proved most successful at trial, with the Stinson jury specifically finding Bard liable for inadequate physician warnings about Perfix Plug risks.
Case Management Orders
Litigation status
MDL 2846 (In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation) is in active settlement administration before Judge Edmund A. Sargus, Jr. in the S.D. Ohio. The October 2024 global settlement framework covering approximately 38,000 claims has entered its Intensive Settlement Process (ISP) phase, with Special Masters Ellen K. Reisman and John Jackson appointed in November 2025 to conduct monthly mediations beginning January 2027 through June 2029.
MDL Track
MDL 2846
S.D. Ohio
Bard/Davol polypropylene hernia mesh
23,695 pending
State Court Activity
15,000+ resolved in Rhode Island state courts per October 2024 settlement
MDL 2846 Leadership
Plaintiff Leadership
Co-Lead Counsel
Timothy M. O'Brien
Levin Papantonio Thomas Mitchell Rafferty & Proctor, P.A.
tobrien@levinlaw.com850-435-7000Liaison Counsel
Executive Committee Chair
Executive Committee Member
Defense Leadership
Liaison Counsel
Geographic exposure
Approximately 38,000 claims covered under the October 2024 global settlement framework; settlement payouts based on tiered, points-based system accounting for injury severity including chronic pain, infection, mesh migration, bowel obstruction, organ perforation, and revision surgery requirements. New cases continue to be filed in 2026 with viability dependent on state-specific statute of limitations (typically 2-6 years from discovery of injury, often measured from first documented complication or revision surgery date).
MDL 2846, In re: Davol Inc/C.R. Bard Inc Polypropylene Hernia Mesh Products Liability Litigation, presided over by Judge Edmund A. Sargus, Jr. Approximately 23,695 actions remained pending as of March 2026 per court docket data, with new filings continuing alongside settlement distributions under the October 2024 global settlement framework.
State court multi-case management, In re: Davol/C.R. Bard hernia mesh multi-case management, Rhode Island Superior Court, No. PC-2018-9999. Included in the October 2024 global settlement covering approximately 38,000 plaintiffs across federal and state proceedings. Site of 2022 state court trial resulting in $4.8 million verdict for Paul Trevino (Ventralex hernia patch case).
Bard and Davol polypropylene hernia mesh products—including Ventralex™ ST, Ventralight™ ST, 3DMax™, Perfix® Plug, Sepramesh™ IP Composite, and Composix® line—implanted across U.S. hospitals and surgical centers over more than two decades. Eligibility requires operative reports or device-identifier labeling confirming specific Bard/Davol product.
Key defendants
C.R. Bard, Inc.
Role: Manufacturer
Core defendant in MDL 2846. Global settlement announced October 2024; CMO #52 (July 6, 2024) imposed Lone Pine requirements and limited stay pending MSA implementation. New filings post-settlement face strict docket control and 14-day pharmacy/physician disclosure requirements.
Davol, Inc.
Role: Manufacturer
Bard subsidiary and co-defendant in MDL 2846. Jointly liable under settlement. Fourth bellwether (Bryan v. C.R. Bard, Inc., 2:18-cv-1440, S.D. Ohio Feb. 1, 2024) resulted in partial summary judgment grant; defense strategy emphasizes device-specific testing and learned intermediary doctrine.
| Defendant | Role | Intelligence Note |
|---|---|---|
| C.R. Bard, Inc. | Manufacturer | Core defendant in MDL 2846. Global settlement announced October 2024; CMO #52 (July 6, 2024) imposed Lone Pine requirements and limited stay pending MSA implementation. New filings post-settlement face strict docket control and 14-day pharmacy/physician disclosure requirements. |
| Davol, Inc. | Manufacturer | Bard subsidiary and co-defendant in MDL 2846. Jointly liable under settlement. Fourth bellwether (Bryan v. C.R. Bard, Inc., 2:18-cv-1440, S.D. Ohio Feb. 1, 2024) resulted in partial summary judgment grant; defense strategy emphasizes device-specific testing and learned intermediary doctrine. |
Timeline
MDL 2846 Created in S.D. Ohio
Judicial Panel on Multidistrict Litigation consolidates federal Bard polypropylene hernia mesh cases as In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation, MDL No. 2846, before Judge Edmund A. Sargus, Jr. in the Southern District of Ohio.
First Bellwether: Defense Verdict in Johns
Jury returns defense verdict for C.R. Bard in Johns v. C.R. Bard, first MDL 2846 bellwether trial involving Ventralight ST mesh. Case No. 2:18-md-02846 (S.D. Ohio).
Second Bellwether: $255K Plaintiff Verdict in Milanesi
Jury awards $255,000 to plaintiff in Milanesi v. C.R. Bard, second MDL 2846 bellwether trial, finding defective design in Ventralex mesh. Case No. 2:18-md-02846 (S.D. Ohio).
Rhode Island State Court: $4.8M Verdict in Trevino
Rhode Island state court jury awards $4.8 million in Trevino v. Davol/Bard, later reduced to $4.55 million on remittitur, providing substantial settlement leverage. Case No. PC-2018-4236 (R.I. Super. Ct.).
Third Bellwether: $500K Plaintiff Verdict in Stinson
Jury awards $500,000 in Stinson v. Davol, third MDL 2846 bellwether trial, finding Bard liable for failure to warn on PerFix Plug. Case No. 2:18-md-02846 (S.D. Ohio).
Becton Dickinson Announces Global Settlement Framework
Becton Dickinson announces global settlement framework covering approximately 38,000 Bard hernia mesh claims; SEC Form 8-K confirms over $1 billion estimated value with no admission of liability.
Qualified Settlement Fund Approved
S.D. Ohio approves Qualified Settlement Fund for MDL 2846, establishing formal settlement administration infrastructure. Case No. 2:18-md-02846 (S.D. Ohio).
Special Masters Appointed for ISP
Court appoints Ellen K. Reisman and John Jackson as Special Masters to oversee Intensive Settlement Process (ISP) scheduled for January 2027 launch. Case No. 2:18-md-02846 (S.D. Ohio).
23,695 Cases Remain Pending in MDL 2846
Monthly status report shows approximately 23,695 actions pending in MDL 2846 as settlement administration continues alongside new filings. Case No. 2:18-md-02846 (S.D. Ohio).
Statute of limitations
MDL 2846 global settlement announced October 2024; over 20,000 claims resolving. New filings post-July 6, 2024 face heightened pleading requirements per CMO #52: plaintiffs must certify under penalty of perjury within 21 days that claims are not time-barred and produce causation expert reports within 90 days. MDL proceedings do not toll state SOLs. Rhode Island state court remains active forum with favorable Anthony discovery rule jurisprudence; $4.8M verdict in Stinson case (August 2022). Judge Sargus imposed strict docket control measures; settlement payouts expected 2025-2026.
Rhode Island
3 years from discovery
Rule: Discovery rule applies per Anthony v. Abbott Labs, 677 A.2d 1036 (R.I. 1996); cause accrues when plaintiff knew or should have known of injury and its causal connection to the product
Discovery: Liberal discovery rule: statute runs from when victim discovers or reasonably should discover wrongdoing by manufacturer, not merely injury occurrence
RI Superior Court (Providence) maintains personal jurisdiction over C.R. Bard; favorable venue for out-of-state plaintiffs. See Recine v. Davol Inc.
⚠Ohio (MDL 2846)
2 years from discovery
Rule: Ohio Rev. Code § 2305.10(C); discovery rule applies for product liability claims
Discovery: Accrual upon discovery of injury and its causal link to the product
MDL 2846 (In re: Davol/C.R. Bard Hernia Mesh Prods. Liab. Litig.) centralized before Judge Edmund A. Sargus, Jr., S.D. Ohio. Post-July 6, 2024 filings subject to strict CMO #52 'Lone Pine' requirements: 14-day pharmacy/physician list, 21-day SOL certification under penalty of perjury, 90-day causation expert report. See CMO #52 (July 6, 2024)
Florida
4 years from discovery
Rule: Fla. Stat. § 95.11(3)(a), (e); discovery rule codified
Discovery: Accrues upon discovery of injury and reasonable connection to product
12-year statute of repose for products liability per § 95.031(2)(b) may bar older implants
Maine
6 years from discovery
Rule: 14 Me. Rev. Stat. Ann. § 752; longest SOL period for product liability
Discovery: Discovery rule applies; accrues upon discovery of injury and cause
Longest available SOL period; favorable for delayed-manifestation mesh injuries
Missouri
5 years from discovery
Rule: Mo. Rev. Stat. § 516.120; discovery rule applies for product liability
Discovery: Accrues upon discovery of injury and its causal connection to product
No statutory repose for product liability claims
North Dakota
6 years from discovery
Rule: N.D. Cent. Code § 28-01-16; longest SOL period for product liability
Discovery: Discovery rule applies; accrues upon discovery of injury and cause
6-year period matches Maine as longest available; favorable for delayed-manifestation cases
Minnesota
4 years from discovery
Rule: Minn. Stat. § 541.05; discovery rule applies for product liability
Discovery: Accrues upon discovery of injury and its causal connection
No statutory repose for product liability; 4-year period favorable for mesh cases
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| Rhode Island | 3 years from discovery | Discovery rule applies per Anthony v. Abbott Labs, 677 A.2d 1036 (R.I. 1996); cause accrues when plaintiff knew or should have known of injury and its causal connection to the product | Liberal discovery rule: statute runs from when victim discovers or reasonably should discover wrongdoing by manufacturer, not merely injury occurrence | RI Superior Court (Providence) maintains personal jurisdiction over C.R. Bard; favorable venue for out-of-state plaintiffs. See Recine v. Davol Inc. |
| ⚠Ohio (MDL 2846) | 2 years from discovery | Ohio Rev. Code § 2305.10(C); discovery rule applies for product liability claims | Accrual upon discovery of injury and its causal link to the product | MDL 2846 (In re: Davol/C.R. Bard Hernia Mesh Prods. Liab. Litig.) centralized before Judge Edmund A. Sargus, Jr., S.D. Ohio. Post-July 6, 2024 filings subject to strict CMO #52 'Lone Pine' requirements: 14-day pharmacy/physician list, 21-day SOL certification under penalty of perjury, 90-day causation expert report. See CMO #52 (July 6, 2024) |
| Florida | 4 years from discovery | Fla. Stat. § 95.11(3)(a), (e); discovery rule codified | Accrues upon discovery of injury and reasonable connection to product | 12-year statute of repose for products liability per § 95.031(2)(b) may bar older implants |
| Maine | 6 years from discovery | 14 Me. Rev. Stat. Ann. § 752; longest SOL period for product liability | Discovery rule applies; accrues upon discovery of injury and cause | Longest available SOL period; favorable for delayed-manifestation mesh injuries |
| Missouri | 5 years from discovery | Mo. Rev. Stat. § 516.120; discovery rule applies for product liability | Accrues upon discovery of injury and its causal connection to product | No statutory repose for product liability claims |
| North Dakota | 6 years from discovery | N.D. Cent. Code § 28-01-16; longest SOL period for product liability | Discovery rule applies; accrues upon discovery of injury and cause | 6-year period matches Maine as longest available; favorable for delayed-manifestation cases |
| Minnesota | 4 years from discovery | Minn. Stat. § 541.05; discovery rule applies for product liability | Accrues upon discovery of injury and its causal connection | No statutory repose for product liability; 4-year period favorable for mesh cases |
Live intelligence
AI litigation brief
Bard Hernia Mesh remains established mass tort / active mdl with 37 current signals in the accepted feed.
Overview
MDL 2846 (In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation) is in active settlement administration before Judge Edmund A. Sargus, Jr. in the S.D. Ohio. The October 2024 global settlement framework covering approximately 38,000 claims has entered its Intensive Settlement Process (ISP) phase, with Special Masters Ellen K. Reisman and John Jackson appointed in November 2025 to conduct monthly mediations beginning January 2027 through June 2029.
Key developments
Trajectory
Court filings and press coverage are both active in MDL 2846, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.
Editorial intelligence
MDL 2846 should stay on the lead docket watch because it is the primary consolidation vehicle for Bard Hernia Mesh.
Generated Aug 12, 2026, 2:00 AM UTC
37 events detected
Google News (10)
Hernia Mesh Lawsuit: Settlement News & Who Qualifies - schmidtandclark.com
Hernia Mesh Lawsuit 2026: Payouts, Eligibility & Filing - lawfold.com
Judge approves surgical mesh class action in bid for compensation - BBC
Mesh Hernia Lawsuit in 2026: Settlements and Payouts - LawFold.com
Surgical Mesh Lawsuit 2026: Payouts and Key Updates - LawFold.com
Best Lawyer for Hernia Mesh Lawsuit in 2026 - LawFold.com
Iowa woman died following hernia repair after nurses dismissed painful post-surgery symptoms: lawsuit - Fox News
Bard Mesh Lawsuit Update 2026: Payouts & Who Qualifies - LawFold.com
Mesh Lawsuit Update 2026: Settlements, Who Qualifies - LawFold.com
Hernia Mesh Lawsuit Average Payout: Full 2026 Guide - LawFold.com
No recent PubMed signals. Monitoring is active — this section updates automatically.
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket filed in JPML: The plaintiffs claim that Davol, Inc. and C.R. Bard, Inc. produced and sold defective hernia mesh devices, leading to injuries such as those related to the defective nature of the products. The involved products include 3DMax Mesh, Bard Mesh, Composix Kugel Hernia Patch, and Ventralex Hernia Patch,
Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation
PACER docket entry from NYED: NOTICE OF REMOVAL by Becton, Dickinson and Company, C.R. Bard, Inc., Davol, Inc. from Supreme Court of the State of New York, County of Queens, case number 11656/2026. ( Filing fee $ 405 receipt number ANYEDC-20436692) (Attachments: # 1 Exhibit A to Notice of Removal, # 2 Exhibit B to Notice of Rem
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
95Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Aug 12, 2026, 2:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
MAUDE
PubMed
Event feed
37
events detected
AI Brief
Bard Hernia Mesh remains established mass tort / active mdl with 37 current signals in the accepted feed.
Overview
MDL 2846 (In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation) is in active settlement administration before Judge Edmund A. Sargus, Jr. in the S.D. Ohio. The October 2024 global settlement framework covering approximately 38,000 claims has entered its Intensive Settlement Process (ISP) phase, with Special Masters Ellen K. Reisman and John Jackson appointed in November 2025 to conduct monthly mediations beginning January 2027 through June 2029.
Key developments
PACER court filing on Dec 31: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation. ‖ schmidtandclark.com news on Jul 31: Hernia Mesh Lawsuit: Settlement News & Who Qualifies - schmidtandclark.com. ‖ MAUDE FDA alert on Jul 31: MAUDE Filing 50103814: 3DMax Light.
Generated Aug 12, 2026, 2:00 AM UTC
Tracked MDLs
MDL 2846
S.D. Ohio
Bard/Davol polypropylene hernia mesh